The Technical Analyst
Onconova Therapeutics Inc [ONTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Onconova Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.47% $0.995
America/New_York / 2 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 20.90 mill |
| EPS: | -0.960 |
| P/E: | -1.040 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 21.00 mill |
| Avg Daily Volume: | 0.126 mill |
| RATING 2024-04-02 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.040 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.18x |
| Company: PE -1.040 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.862 (-13.39%) $-0.133 |
| Date: 2024-04-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.634 - 0.758 ( +/- 8.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-13 | Guerin Mark Patrick | Buy | 8 666 | Common Stock |
| 2024-03-14 | Guerin Mark Patrick | Sell | 2 591 | Common Stock |
| 2024-03-13 | Guerin Mark Patrick | Sell | 8 666 | Restricted Stock Units |
| 2024-03-13 | Fruchtman Steven M | Buy | 23 111 | Common Stock |
| 2024-03-14 | Fruchtman Steven M | Sell | 8 727 | Common Stock |
| INSIDER POWER |
|---|
| 76.11 |
| Last 95 transactions |
| Buy: 2 889 396 | Sell: 191 603 |
Forecast:
16:00 - $0.985
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.985
Forecast 2: 16:00 - $0.985
Forecast 3: 16:00 - $0.985
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.995 (-0.47% ) |
| Volume | 1.255 mill |
| Avg. Vol. | 0.126 mill |
| % of Avg. Vol | 993.06 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ONTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ONTX
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Latest Press Releases
2024-04-02 07:15:00 - Press Release
Traws Pharma Announces New Employee Inducement Grants
Newtown, pa., april 02, 2024 (globe newswire) -- traws pharma, inc. (nasdaq: traw, “traws”, the “company”) today announced it has granted equity awards to new employees who joined traws in connection with the recent acquisition of trawsfynydd therapeutics, inc. by onconova therapeutics, inc. (the “merger”).
2024-03-08 08:00:00 - Press Release
Onconova Therapeutics' Rigosertib Poster Selected For Aacr 2024
Newtown, pa., march 08, 2024 (globe newswire) -- onconova therapeutics, inc. (nasdaq: ontx), (“onconova” or “the company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the company will present an abstract related to preclinical studies conducted by the company and its collaborators to further characterize the mechanism of rigosertib at the american association for cancer research annual meeting 2024 (aacr 2024), taking place april 5-10, 2024 in san diego, ca.
2023-12-08 16:05:00 - Press Release
Onconova Therapeutics' Preclinical Narazaciclib Data At Sabcs Highlights Differentiated Anti-tumor Activity V. Other Cdk4/6i's
Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved cdk4/6 inhibitors data support the potential use of narazaciclib in breast and ovarian cancers narazaciclib progressing towards rp2d and preparation for registrational studies, with a planned update in h1 2024 newtown, pa., dec. 08, 2023 (globe newswire) -- onconova therapeutics, inc. (nasdaq: ontx), (“onconova” or “the company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preclinical data highlighting narazaciclib's multi-kinase profile, broad anti-tumor activity and increased anti-tumor immunity, compared to palbociclib and other cdk4/6 inhibitors, in a poster presented at the san antonio breast cancer symposium (sabcs) on december 8, 2023.
2023-11-28 08:00:00 - Press Release
Onconova Therapeutics To Present At Noblecon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference
Newtown, pa., nov. 28, 2023 (globe newswire) -- onconova therapeutics, inc. (nasdaq: ontx), (“onconova”, the “company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that steven fruchtman, m.d.
2023-11-14 16:05:00 - Press Release
Onconova Therapeutics Reports Corporate Update And Announces Third Quarter 2023 Financial Results
Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile update on the registrational preparations for the narazaciclib program and the rigosertib trial plan expected in the first half of 2024 company to host conference call and webcast at 4:30 p.m. et on tuesday, november 14, 2023 newtown, pa.
Latest News
2023-11-28 08:00:00 - GlobeNewsWire
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference
NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D.
2023-11-14 20:18:07 - Seeking Alpha
Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Steve Fruchtman - President and CEO Victor Moyo - Chief Medical Officer Mark Guerin - Chief Operating Officer and CFO Meena Arora - VP of Global Medical Affairs & Research and Development, Conference Call Participants Edouard Mullarky - Guggenheim Partners Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Capital Markets James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Welcome to Onconova Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call.
2023-11-07 16:05:00 - GlobeNewsWire
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023.
2023-09-28 08:00:00 - GlobeNewsWire
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract reporting the use of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB) associated with advanced/metastatic squamous cell carcinoma (SCC) will be presented in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2023 Congress taking place October 11-14 in Berlin, Germany.
2023-08-10 21:08:05 - Seeking Alpha
Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Steve Fruchtman - President and CEO Dr. Victor Moyo - Consultant Chief Medical Officer Mark Guerin - Chief Operating Officer and CFO Fred Frullo - Vice President, Regulatory Affairs and Quality Assurance Conference Call Participants Edouard Mullarky - Guggenheim Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty] Dr. Steve Fruchtman Sarah, excuse me, you are coming in and out and I don't know if other people hear.
2023-05-15 21:11:06 - Seeking Alpha
Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Bruce Mackle - Managing Director, LifeSci Advisors Steven Fruchtman - President and Chief Executive Officer Michael Saunders - Interim Chief Medical Officer Mark Guerin - Chief Operating Officer and Chief Financial Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Life Science Partners Operator Ladies and gentlemen, thank you for standing by.
2023-05-15 18:59:34 - Zacks Investment Research
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
Onconova Therapeutics, Inc. (ONTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.20 per share a year ago.
2023-05-04 16:05:00 - GlobeNewsWire
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023
2023-04-25 11:28:44 - PennyStocks
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029%
Analysts say these are penny stocks to buy but do you agree? The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-04-24 13:15:26 - PennyStocks
5 Hot Penny Stocks To Watch With The Stock Market Down This Week
Hot penny stocks to watch this week. This is a significant week for earnings, and mega-cap tech names will headline what's sure to be a volatile week. Next week, the action continues with the upcoming Fed meeting and another rate hike decision.